Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mutations in the immunoglobulin-like domain of gp190, the leukemia inhibitory factor (LIF) receptor, increase or

Juliette Bitard1, Sophie Daburon, Laurence Duplomb

  • 1CNRS UMR 5540, Université de Bordeaux 2, 146 rue Léo Saignat, 33076 Bordeaux, France.

The Journal of Biological Chemistry
|February 26, 2003
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ALG14 Variants Contribute to a Congenital Disorder of Glycosylation Characterized by Congenital Myasthenia and Epilepsy.

HGG advances·2026
Same author

Preformed Anti-DQ Alpha Donor-specific Antibodies and the Risk of Antibody-mediated Rejection After Kidney Transplantation.

Transplantation·2026
Same author

Antihuman leukocyte antigen antibodies and risk of fetal growth restriction.

American journal of obstetrics and gynecology·2026
Same author

Optimizing risk-benefit in highly sensitized kidney recipient antigen delisting increasing donor access.

Kidney international·2026
Same author

Characterisation of the Novel HLA-B*52:131 Allele by Sequencing-Based Typing.

HLA·2026
Same author

B-cell maturation antigen-Targeted T-cell Engager Therapy Combined with B-cell Depletion for Treatment of Refractory HLA Sensitization.

Kidney international·2026

Researchers identified a specific binding site on the gp190 protein

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Structural Biology

Background:

  • The leukemia inhibitory factor (LIF) receptor is crucial for cellular processes.
  • It consists of gp190 (low affinity) and gp130 (high affinity) chains.
  • The gp190 ectodomain features an immunoglobulin-like (Ig-like) domain, adding complexity.

Purpose of the Study:

  • To investigate the role of the gp190 Ig-like domain in LIF binding.
  • To identify specific amino acid residues responsible for differential LIF binding affinity between human and murine gp190.
  • To understand how structural variations in the Ig-like domain influence receptor function.

Main Methods:

  • Alanine-scanning mutagenesis was employed on the gp190 Ig-like domain.
  • Site-directed mutagenesis was used to introduce specific residue changes (Q251E, N321D).

Related Experiment Videos

  • Structural modeling was utilized to visualize the LIF binding site.

    • Main Results:

    • A LIF binding site was mapped to the carboxyl terminus of the Ig-like domain, involving Phe-328.
    • Mutating specific residues (Q251E, N321D) to their murine orthologs significantly enhanced human LIF binding affinity.
    • These residues form a unique binding site within the Ig-like module.

    Conclusions:

    • The Ig-like domain of gp190 plays a definitive role in LIF binding.
    • Limited amino acid alterations can significantly modulate LIF receptor affinity.
    • This finding has implications for understanding and engineering cytokine receptor function.